The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.
The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.
The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.
The conversation is about using Maxogen-X, a topical solution containing minoxidil, finasteride, tretinoin, and azelaic acid, for hair loss treatment. Users discuss their experiences, including initial shedding and the hope for thicker hair, while sharing progress updates.
A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
A user is seeking recommendations for purchasing Minichek 5% solution, a PG-free minoxidil, due to a contact allergy to propylene glycol. They are looking for an affordable option comparable in price to Kirkland or Amazon brand minoxidil.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
A user with diffuse thinning, currently using finasteride, biotin, minoxidil, and nizoral shampoo, is considering a topical solution called "82M" but is skeptical due to its high cost and lack of supporting research. They seek others' experiences with "82M."
A user shared a list of natural supplements they tried that did not stop their male pattern baldness (MPB), including vitamin D, biotin, and various oils. The conversation includes skepticism and jokes about one of the methods, injecting jellyfish mucus into testicles, and mixed opinions on the effectiveness of natural treatments.
User regrew lost hair using microneedling, minoxidil, finasteride, Nizoral, fish oil, and collagen peptide. Progress was slow but constant, and patience was important.
A 24-year-old with thinning hair and receding sides is considering using Minoxidil and finasteride to improve hair thickness. They are seeking general expectations for these treatments, acknowledging individual results may vary.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hair follicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.
A 28-year-old male is experiencing excessive hair shedding despite using oral and topical minoxidil, and occasionally using ketoconazole shampoo. He is considering trying GHK-Cu serums but cannot use finasteride.
A 26-year-old male with grade 3 hair loss is using 2.5 mg oral minoxidil, 1 mg finasteride, 5% minoxidil, ketoconazole shampoo, and kLM d3. He plans to post progress pictures every 6 weeks and is seeking suggestions.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
Oral minoxidil was ineffective for OP, causing hair loss and unwanted body hair, while topical minoxidil showed significant regrowth. OP is switching to topical minoxidil with glycerin due to scalp issues with propylene glycol.